Sugi Predict

Sugi Predict / Compounds / SCHEMBL499428

SCHEMBL499428

SCHEMBL499428

O=C(Cc1ccc(CC(=O)ON2C(=O)CCC2=O)cc1)ON1C(=O)CCC1=O

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.46
▸ MAPK1 P28482 2/20 0.46
▸ HPGD P15428 1/20 0.46
▸ CYP4F2 P78329 1/20 0.39
▸ CYP4A11 Q02928 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ MGLL Q99685 4/20 0.37
▸ PAM P19021 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ CTSG P08311 1/20 0.35
▸ CMA1 P23946 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ PARL Q9H300 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ ALOX12 P18054 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5852228 0.93 CA2 (0.46) KMT2AMAPK1HPGDALDH1A1L3MBTL1
SCHEMBL9465229 0.91 MGLL (0.48) KMT2AMAPK1HPGDALDH1A1L3MBTL1
SCHEMBL15896085 0.91 KMT2A (0.44) KMT2AMAPK1HPGDALDH1A1L3MBTL1
SCHEMBL17356716 0.91 KMT2A (0.41) KMT2AMAPK1HPGDCYP4F2CYP4A11
SCHEMBL20530034 0.91 KMT2A (0.41) KMT2AMAPK1HPGDCYP4F2CYP4A11
SCHEMBL2450503 0.91 KMT2A (0.57) KMT2AMAPK1HPGDALDH1A1L3MBTL1
SCHEMBL24969572 0.88 KMT2A (0.46) KMT2AMAPK1HPGDALDH1A1L3MBTL1
SCHEMBL31225415 0.88 SENP1 (0.48) KMT2AMAPK1HPGDTSHRPARL
SCHEMBL31225518 0.88 SMN1; SMN2 (0.54) KMT2AHPGDALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL4738882 0.88 LMNA (0.51) KMT2AMAPK1HPGDALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10689430-B2 Insulin receptor partial agonists MERCK SHARP & DOHME CORP. (US) 2020-06-23 — — US disclosed
US-20190177393-A1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME CORP. (US) 2019-06-13 — — US disclosed
WO-2017205309-A1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME CORP. (US) 2017-11-30 — — WO disclosed
US-8436183-B2 Synthetic multimerizing agents ARIAD PHARMACEUTICALS, INC. (US) 2013-05-07 — — US disclosed
US-20120130076-A1 Synthetic Multimerizing Agents ARIAD PHARMACEUTICALS, INC. (US) 2012-05-24 — — US disclosed
US-8106191-B2 Compounds based on N- acyl-pipecolyl and N-acyl-prolyl ligand moieties for multimerizing chimeric proteins containing immunophilin-derived domains ARIAD PHARMACEUTICALS, INC. (US) 2012-01-31 — — US disclosed
EP-0888303-B1 SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS ARIAD PHARMA INC (US) 2010-04-21 — — EP disclosed
EP-0776327-B1 NEW MULTIMERIZING AGENTS ARIAD GENE THERAPEUTICS INC (US) 2005-07-06 — — EP disclosed
US-20040006233-A1 Synthetic multimerizing agents ARIAD PHARMACEUTICALS, INC. 2004-01-08 — — US disclosed
US-20030036654-A1 Synthetic multimerizing agents HOLT DENNIS A (US) 2003-02-20 — — US disclosed
US-20020161240-A1 Synthetic multimerizing agents ARIAD GENE THERAPEUTICS, INC. 2002-10-31 — — US disclosed
US-6150527-A Synthetic multimerizing agents ARIAD PHARMACEUTICALS, INC. (US) 2000-11-21 — — US disclosed
US-6133456-A DIMERS OF THE MACROCYCLIC NATURAL PRODUCT, FK506, COVALENTLY ATTACHED TO EACH OTHER VIA A SYNTHETIC LINKER MOIETY ARIAD GENE THERAPEUTICS, INC. (US) 2000-10-17 — — US disclosed
EP-0888303-A1 SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS ARIAD GENE THERAPEUTICS, INC. (US) 1999-01-07 — — EP disclosed
EP-0776327-A4 NEW MULTIMERIZING AGENTS ARIAD GENE THERAPEUTICS INC (US) 1997-12-10 — — EP disclosed
WO-1997031898-A1 SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS ARIAD GENE THERAPEUTICS, INC. (US) 1997-09-04 — — WO disclosed
EP-0776327-A1 NEW MULTIMERIZING AGENTS ARIAD GENE THERAPEUTICS, INC. (US) 1997-06-04 — — EP disclosed
WO-1996006097-A1 NEW MULTIMERIZING AGENTS ARIAD GENE THERAPEUTICS, INC. (US) 1996-02-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161240-A1 Synthetic multimerizing agents SSB, F13B, LCP2 KMT2A 2738/4885MAPK1 2610/4885HPGD 4096/4885
US-20120130076-A1 Synthetic Multimerizing Agents FKBP1B, FKBP2, FKBP14 KMT2A 1904/4885MAPK1 4279/4885HPGD 3763/4885
US-20040006233-A1 Synthetic multimerizing agents FKBP1B, FKBP2, FKBP14 KMT2A 1992/4885MAPK1 4400/4885HPGD 3757/4885
US-20190177393-A1 INSULIN RECEPTOR PARTIAL AGONISTS INSR, GPR119, IRS1 KMT2A 4174/4885MAPK1 3170/4885HPGD 3295/4885
US-10689430-B2 Insulin receptor partial agonists INSR, GPR119, IRS1 KMT2A 4174/4885MAPK1 3170/4885HPGD 3295/4885
US-20030036654-A1 Synthetic multimerizing agents FKBP1B, FKBP2, FKBP14 KMT2A 1864/4885MAPK1 4212/4885HPGD 3558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.